MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 133 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q4 2023. The put-call ratio across all filers is 1.05 and the average weighting 0.8%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,313,560,041 | 32.87% |
| Cormorant Asset Management, LP | 8,494,151 | $512,961,779 | 24.50% |
| Darwin Global Management, Ltd. | 1,039,289 | $62,762,663 | 12.32% |
| Ally Bridge Group (NY) LLC | 143,479 | $8,664,697 | 5.16% |
| Ghost Tree Capital, LLC | 250,000 | $15,097,500 | 4.94% |
| 5AM Venture Management, LLC | 302,630 | $18,275,826 | 4.85% |
| MPM BioImpact LLC | 294,576 | $17,789,445 | 4.16% |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 228,992 | $13,828,827 | 3.15% |
| STEMPOINT CAPITAL LP | 167,851 | $10,136,522 | 2.70% |
| Avoro Capital Advisors LLC | 2,580,000 | $155,806,200 | 2.15% |